Last updated on August 2019
Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Chronic renal failure | chronic renal insufficiency | Non Valvular Atrial Fibrillation
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
Inclusion Criteria:
- male and female patients, age 18 years
- CKD with eGFR 15 - 49 mL/min per 1.73 m2
- non-valvular atrial fibrillation (NVAF) with indication for anticoagulation therapy
- a treatment strategy for the 3 previous months before enrolment with either: rivaroxaban or VKA (OAC cohorts) or no anticoagulation (no AC cohort)
- informed consent
- availability for follow up
- life expectancy of 6 months
Exclusion Criteria:
- exclusion criteria according to the local product information for the respective anticoagulation treatment
- planned treatment with other anticoagulants
- expected renal-replacement therapy within the next 3 months
